Overview
HBOT is widely used in professional sports (NFL, NBA, Premier League) for muscle recovery, injury rehabilitation, and reducing delayed-onset muscle soreness. The evidence base is largely anecdotal with limited controlled trials. Mild HBOT (1.3 ATA soft-shell) is more common than clinical HBOT in this setting.
Elite athlete HBOT has grown substantially over the past decade. Many professional teams and individual athletes own or routinely use HBOT chambers. The appeal is multifactorial — reduced delayed-onset muscle soreness (DOMS) after training, accelerated soft-tissue injury healing, and perceived performance recovery between competitions.
The scientific evidence base lags clinical use. A small number of controlled trials have examined specific sports-related endpoints with mixed results. Branco et al. 2016 meta-analysis of HBOT for athletic performance concluded evidence was limited. Case studies and testimonials dominate the literature, which should be interpreted cautiously.
The pressure used also varies widely in sports settings. Mild HBOT at 1.3 ATA (soft-shell home chambers) is common; clinical HBOT at 2.0+ ATA less so outside specific injury rehabilitation. The pressure-dependent evidence noted elsewhere for neurological indications also applies to sports — but without the trial base to anchor recommendations.
How HBOT Works for This Condition
Hypothesised mechanisms include reduced muscle inflammation, improved tissue oxygenation during recovery, and support of soft-tissue repair. Reduction in DOMS has been reported in some studies.
GRADE Evidence Rating
Babul 2003 RCT negative for DOMS. No large RCT support despite marketing.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | Moderate |
| Consistency | Mostly negative |
| Directness | Direct |
| Precision | Imprecise |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 5–20 sessions, varied protocols (1.3–2.0 ATA) |
|---|---|
| Evidence level | Limited — Mostly anecdotal |
| FDA status | Not FDA-approved |
Evidence Base
Case studies and small trials dominate. Branco et al. 2016 meta-analysis concluded evidence is limited. UHMS Tier 3 (investigational).
Cautions & Considerations
- Evidence base is limited.
- Marketing claims often exceed the data.
- Not a substitute for standard sports medicine care.
- Soft-shell 1.3 ATA has weaker evidence than clinical HBOT.
Key Research & References
- Branco et al. 2016 meta-analysis
- Various case studies
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
Does HBOT improve athletic performance?
Direct performance improvement is not well supported by controlled trials. HBOT may support recovery from injury or training stress, but evidence is limited.
What pressure for sports recovery?
Varies widely. Mild HBOT at 1.3 ATA is common in home/team settings; clinical pressures (2.0 ATA) are used for specific injury rehabilitation. Pressure-dependent evidence remains thin.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.